So this looked at patients with ER-positive, HER2-Positive metastatic breast cancer who had received induction chemotherapy with H with or without P. Patients then were randomized to continue ...
Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges ...
Investing.com - Guggenheim has reiterated its Buy rating on AstraZeneca (NASDAQ:AZN) (AZN:LN) with a price target of ...
The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
Clinicians treating patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer are navigating ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback